Tumor invasion and metastasis are important aspects of tumor progression, and the formation of tumor metastasis is a principal contributing factor to cancer morbidity and mortality (1 ) . Basal membrane and extracellular matrix represent two physical barriers to malignant invasion: their degradation by matrix metalloproteinases (MMPs) plays a key role in tumor progression and metastatic spread (2, 3 ) .
MMP expression in tumors is regulated in a paracrine manner by growth factors and cytokines secreted by tumor-infiltrating inflammatory cells as well as by tumor or stromal cells. Recent studies have suggested continuous cross-talk between tumor cells, stromal cells, and inflammatory cells during the invasion process (1, 2, 4, 5 ) . Expression of most MMPs is usually low in tissues and is induced when remodeling of extracellular matrix is required. MMP gene expression is primarily regulated at the transcriptional level, but there is also evidence of modulation of mRNA stability in response to growth factor and cytokines (2, 6 ) .
Several lines of evidence indicate a significant association between variations in MMP genes and susceptibility to cancer. The promoter region of inducible MMP genes (i.e., MMP1 and MMP3) shows remarkable conservation of regulatory elements, and their expression is induced by growth factors, cytokines, and other environmental factors, such as contact with extracellular matrix (7) (8) (9) .
Recently, a naturally occurring sequence variation in the human MMP1 gene promoter was reported (10 ) . Many studies have demonstrated the correlation between the 2G allele and several malignant tumors with different histogenetic origins (11) (12) (13) (14) (15) . Recently, our group demonstrated a correlation between the MMP3 polymorphism and breast cancer (16 ) .
Matrilysin (MMP7) is a protease with broad substrate specificity, being able to degrade elastin, proteoglycans, fibronectin, and type IV collagen. MMP7 is among the smallest members of the MMP family (17 ) .
MMP7 was first characterized from a human rectal carcinoma cell line, and overexpression of MMP7 has been shown to correlate with Duke's stage and increased metastatic potential in colorectal carcinoma (CRC) (18, 19 ) . Jormsjö et al. (20 ) recently described two common polymorphisms in the promoter region of the MMP7 gene that are functional in vitro and seem to influence coronary artery dimensions. Both polymorphisms influenced the binding of nuclear proteins. Furthermore, in transient transfection studies, the combination of the two rare alleles conferred an increased promoter activity.
The aim of this prospective study was to investigate a possible correlation between MMP7 promoter polymorphisms and CRC clinical phenotypes, specifically the ability of genetic analysis to identify a subgroup of CRC patients with a disease that appears more aggressive or prone to metastasis.
The study started during June 2000, and recruitment was stopped during June 2002. Our Institutional Ethical Committee approved this study, and informed consent was obtained from patients and controls.
MMP7 gene promoter sequences were obtained from peripheral blood samples from 58 consecutive patients with CRC of different stages who underwent surgery and from 111 sex-and age-matched healthy individuals (control group). CRC patients were 38 males and 20 females (median age, 68 years; range, 32-88 years). Patients and controls were all Italian. CRC patients were grouped according to Duke's classification, as modified by Astler and Coller (21 ) , on the basis of the postoperative histopathologic evaluation. The group assignment was then reevaluated at the end of the follow-up period, which ranged from 6 to 30 months (median, 21 months). The 58 patients with CRC were assigned to two subgroups according to the presence (Mϩ) or absence (MϪ) of detectable metastasis at the time of diagnosis and at the end of the follow-up.
Genetic polymorphisms were detected with PCR followed by direct sequencing. The Insta Gene (Bio-Rad) commercial reagent set was used for DNA extraction from whole blood. The PCR reaction for MMP7 was carried out in a total volume of 25 L with 5 L of extracted genomic DNA; 100 M dATP, dGTP, dTTP and dCTP; 1.5 mM MgCl 2 ; 1 U of Taq Gold polymerase; and the two primers, forward and reverse, each at a concentration of 80 nM. The primers were designed with the Primer Express software. The MMP7 primer sequences were as follows: forward primer, 5Ј-CCTGAATGATACCTATGAGAG-CAGTC-3Ј; reverse primer, 5Ј-AGAGTCTACAGAACTT-TGAAAGTATGTGTTATT-3Ј. The PCR began with a 5-min incubation at 94°C to activate the enzyme, followed by 35 cycles of 20 s at 94°C, 20 s at 55°C, and 30 s at 72°C.
The amplification was verified on an agarose gel (2%) followed directly by sequencing with an automatic sequencer using fluorescent DNA capillary electrophoresis (ABI Prism 310; Applied Biosystems). The forward primer was used for the sequencing primer.
Differences between groups were examined by the 2 test or Fisher exact test when appropriate. Odds ratios (ORs; approximate relative risk) were calculated as an index of the association of the MMP genotypes with each phenotype. For each OR, two-tailed probability values and 95% confidence intervals (CIs) were calculated. P Ͻ0.05 was assumed as the cutoff for statistical significance. All statistical analyses were two-sided and were performed with Stata Statistical Software (Stata Corporation). The polymorphism distributions in patients and controls were, as expected, according to Hardy-Weinberg equilibrium.
In CRC patients, the number of Ϫ181G homozygotes [patients vs controls, 15 (26%) vs 14 (13%); OR, 2.41; 95% CI, 0.98 -5.89; P ϭ 0.03] and the T allele frequency in position Ϫ153 (0.11 vs 0.05; OR, 2.20; 95% CI, 0.89 -5.48; P ϭ 0.05) were significantly higher than in controls. The Ϫ181G/Ϫ153T haplotype was more represented, although not significantly, in CRC patients than in controls (P ϭ 0.08; Table 1 ).
Subgroups were compared with controls and among allelic variants. The Ϫ153C/T promoter allelic variant distribution was not statistically significantly different among the subgroups. For the Ϫ181A/G promoter polymorphism, however, we found a strong correlation between Ϫ181G homozygosity and the Mϩ subgroup at the time of diagnosis [Mϩ vs MϪ, 9 (56%) vs 6 (14%); OR, 7.5; 95% CI, 2.07-27.19; P ϭ 0.0013].
The frequency of the Ϫ181G allele was not statistically different between controls and metastasis-free (MϪ) patients (P ϭ 0.95). Moreover, the Ϫ181A/G polymorphism was correlated with lymph node metastasis at the beginning of follow-up. In the N1ϩN2 patients, the number of Ϫ181G homozygotes and G allele frequencies were greater than in the N0 patients [number of homozygotes, 13 (35%) vs 2 (10%; P ϭ 0.03); G allele frequency, 0.53 vs 0.36 (P ϭ 0.02), respectively].
Our data demonstrate, for the first time, that the two common polymorphisms on MMP7 promoter region are correlated to CRC susceptibility. In addition, our results may suggest that Ϫ181G homozygosity is associated with the presence of distant metastasis as well as lymph node involvement. From this point of view, G homozygosity might be considered as a factor of worse prognosis.
MMP7 has unique characteristics, such as a minimum MMP structure, wide spectrum of substrate specificity, and potency to start an activation cascade of MMPs (17 ) . In addition to its overexpression in a variety of cancer tissues, in vitro and animal data suggest that MMP7 may play a key role in tumor invasion and metastasis as well as tumor initiation and growth. Many studies have reported that MMP7 mRNA is overexpressed in human CRC and is correlated with increasing Duke's stage (22) (23) (24) .
Recently Jormsjö et al. (20 ) identified two novel polymorphisms in the MMP7 promoter region. Electrophoretic mobility shift assay results demonstrated that the Ϫ181A/G and the Ϫ153C/T polymorphisms influence the binding of nuclear protein(s). Furthermore, basal promoter activity was higher in promoter constructs harboring the combination of the two rare alleles in transient transfection studies. In our study the Ϫ181G/ Ϫ153T haplotype was more represented in CRC patients than in controls, although statistical significance was not reached (19% vs 10%; P ϭ 0.08). We did observe a statistically significant correlation between the Ϫ181A/G substitution and susceptibility, invasiveness, and prognosis in CRC. In CRC patients, the frequency of Ϫ181G homozygotes was 2-fold higher than in controls, and 4.2-fold higher in patients who developed metastasis at the end of the follow-up (OR, 4.2; 95% CI, 1.19 -14.59; P ϭ 0.024). Lymph node metastasis is the most important prognostic factor in colon cancer, and the Ϫ181A/G substitution correlated well with lymph node involvement at the time of diagnosis. The G allele frequency was 2.5-fold higher in lymph node-positive patients than in lymph node-negative ones (OR, 2.49; 95% CI, 1.14 -5.42; P ϭ 0.02). The Ϫ153C/T polymorphism seems in our series less involved in CRC susceptibility, although the mutant T allele was more represented in CRC patients (P ϭ 0.05).
In conclusion, our study suggests that the presence of G allele for the MMP7 gene promoter sequence may be a facilitating factor for cancer growth, lymph node invasion, and metastasis in CRC patients. The good correlation of lymph node involvement and distant metastasis with Ϫ181G homozygosity might suggest the use of this common polymorphism as a prognostic factor at the beginning of follow-up for influencing the decision for adjuvant therapy in N0M0 patients. Our data suggest a role of MMP7 in the matrix remodeling associated with CRC. However, no firm conclusions regarding the clinical sig- Familial Mediterranean fever (FMF) is an autosomalrecessive disorder (MIM 249100) characterized by recurrent attacks of fever and serositis, affecting principally Sephardic Jewish, Armenian, Arab, and Turkish populations. Early diagnosis is important to initiate colchicine therapy, which prevents the occurrence of attacks and of renal amyloidosis, the major complication of the disease. The identification of MEFV (1, 2 ) , the gene responsible for the disease, allowed the use of an early molecular test of diagnostic value for FMF patients (3 ), which negates the needs for unnecessary invasive investigations. The MEFV gene, located on chromosome 16p13.3, contains 10 exons and encodes the marenostrin/pyrin protein, a molecule acting as a regulator of the proinflammatory interleukin-1-dependent pathway and of the apoptosis mediated by the apoptosis-associated Speck-like protein containing a CARD (ASC) (4, 5 ) , and which belongs to the death domain-fold family (6 ) .
More than 40 different FMF-associated mutations have been described to date (7 ), the most frequent ones being located in exon 10. Indeed, the M694V, V726A, M680I, and M694I mutations account for 65-95% of FMF alleles depending on the ethnic origin of the patient (8 ) . E148Q is a frequent sequence variation situated in exon 2, but its involvement in the development of the disease remains controversial (9 ) . The molecular diagnosis of FMF is based on various methods, including tedious and timeconsuming scanning techniques such as denaturing gradient gel electrophoresis (DGGE) (3 ) or direct sequencing (10 ) . Restriction enzyme analysis enables the detection of known mutations but still requires multiple DNA amplifications. An in-house amplification refractory mutation system has been designed, but it detects only three mutations (11 ) . Because the spectrum of the most frequent mutations in FMF has been characterized in all at-risk populations, a new method aimed at identifying a set of selected common mutations in a single step would be less time-consuming and would provide greater throughput than previous methods.
We investigated the practicality and the reliability of the FMF StripA ssay (ViennaLab Labordiagnostika), the first commercially available assay that allows the detection of 12 MEFV gene mutations in 1 working day. Twelve mutations located in exons 2 (E148Q), 3 (P369S), 5 (F479L),
